Summary Screen-detected breast cancers are smaller than those detected in symptomatic populations and, for any given size, they are associated with fewer lymph node metastases. The management of axillary lymph nodes in patients with screen-detected breast cancer (Crisp et al., 1993; Tabar et al., 1992) . For any given size, screen-detected cancers are associated with fewer lymph node metastases than those detected in non-screened populations (Anderson et al., 1991). However, the Edinburgh Breast Screening Trial reported that these tumour variables differ between cancers detected at the prevalence (initial screen) and incidence (second or subsequent) screening rounds (Anderson et al., 1986 (Anderson et al., , 1991. Although patient numbers in this study were relatively small, lymph node positivity was found to be 24.5% in the prevalence screen (PS) and 31.3% for incidence screen (IS)-detected cancers.
Breast screening aims to reduce mortality by early detection and treatment of breast cancer. For this to be achieved, screen-detected cancers should have a better prognosis than those presenting symptomatically. Screen-detected breast cancers are smaller than those detected in a non-screened population with more favourable histological grade and type (Crisp et al., 1993; Tabar et al., 1992) . For any given size, screen-detected cancers are associated with fewer lymph node metastases than those detected in non-screened populations (Anderson et al., 1991) . However, the Edinburgh Breast Screening Trial reported that these tumour variables differ between cancers detected at the prevalence (initial screen) and incidence (second or subsequent) screening rounds (Anderson et al., 1986 (Anderson et al., , 1991 . Although patient numbers in this study were relatively small, lymph node positivity was found to be 24.5% in the prevalence screen (PS) and 31.3% for incidence screen (IS)-detected cancers.
The optimum surgical management of axillary lymph nodes in women with symptomatic or screen-detected breast cancer remains highly controversial. Some authors recommend axillary staging in all patients with operable invasive breast cancer to gain maximum prognostic information and to allow selection of patients for systemic adjuvant therapy (Fentiman, 1991) . However, if we could identify those patients with breast cancer at low risk of nodal involvement, the number of patients needing axillary dissection would be reduced, resulting in a subsequent decrease in patient morbidity, operating time and cost. Several authors have suggested that axillary dissection can be abandoned for small (< 1 cm) symptomatic cancers, in view of the low rates of lymph node involvement. Instead patients could be selected for adjuvant therapy on the basis of primary tumour characteristics alone, with axillary dissection adding little if anything to the decision-making process (Silverstein et al., 1994; Chada et al., 1994; Cady, 1994 The United Kingdom breast screening guidelines target the detection of small breast cancers, but for screening to succeed and reduce the mortality from breast cancer lesions must be detected before the development of nodal metastases (Crisp et al., 1993) . Breast screening theory supposes that prevalence screens are biased towards the detection of slow-growing, less aggressive cancers, whereas incidence screens detect smaller, faster growing and biologically more aggressive lesions, because of the phenomenon of length time bias (Cole, 1980) . Our results are compatible with breast screening theory.
In the two screening rounds, invasive cancers of similar histological type and almost identical grade were detected. A greater proportion of cancers detected in the FIS were < 10 mm in size, but despite this overall lymph node positivity was significantly higher in the FIS. Axillary lymph nodes are the main site of regional metastases from breast cancer. Lymph node status is recognised to be the most useful marker of distant metastatic spread and prognosis in patients with breast cancer (Fisher et al., 1975 (Fisher et al., , 1983 Valagussa et al., 1978) and is the basis for several prognostic indices (Todd et al., 1987; Galea et al., 1992) . Despite this, the management of the axilla in patients with screen-detected and early symptomatic breast cancer is controversial and ranges from no surgical intervention, to axillary sampling of ten nodes and to formal level III axillary clearance. It is not the purpose of this paper to discuss the relative merits of each of these management options, however the quality assurance guidelines laid down for surgeons managing symptomatic breast cancer advise that axillary surgery of some type must be performed in all cases (British Association of Surgical Oncologists, 1995) .
For screen-detected cancers, our unit policy is to perform a level III axillary clearance for women considered to be at significant risk of having nodal metastases (i.e. > 10%). For patients with cancers at low risk (< 10%) of nodal involvement, no form of axillary surgery is performed. This policy is recommended by other authors (Silverstein et al., 1994; Chada et al., 1994; Cady, 1994) and can be justified if this important subgroup of women can be accurately identified preoperatively.
For breast cancers that present symptomatically, axillary dissection should ideally be performed at the same time as therapeutic excision of the primary tumour, the diagnosis having been made preoperatively by fine-needle aspiration cytology. However, stereotactic cytological assessment of small impalpable screen-detected cancers can be difficult, and many of our patients require diagnostic localisation biopsy.
In our previous study, PS-detected cancers < 10 mm diameter were associated with lymph node metastases in only 5% of cases. No grade I cancers <30 mm were associated with nodal involvement. We recommend that this subgroup of patients can be spared axillary surgery after localisation biopsy. This reduces morbidity and operating time, with little loss of prognostic information.
Apart from grade I cancers, this low rate of nodal metastases was not found in cancers detected at the FIS. For any given size, cancers detected at our PS have fewer lymph node metastases than those detected at the FIS (Figure 2) . Their relationship between size and lymph node status seen for PS-and FIS-detected cancers is similar to that seen between screen-detected and symptomatic cancers, with the latter having a higher incidence of nodal involvement (Crisp et al., 1993) . Moreover, the frequency of node metastases in the FIS-detected cancers is equivalent to that seen in a symptomatic breast cancer population (Fisher et al., 1983) .
The implementation of our previous recommendations led initially to fewer women with screen-detected cancer undergoing axillary surgery in Manchester, UK. In this study, patients who did not undergo axillary clearance were assumed to be lymph node negative, and we calculated lymph node positivity as a proportion of the total invasive group, and not just of those undergoing axillary dissection. If we consider axillary node involvement as a percentage of those undergoing axillary surgery, the frequency of nodal metastasis in the FIS cancer is nearly 9% higher at 38.4%.
The incidence of lymph node positivity for non-screened, symptomatic cancers has been reported to be between 40% and 50% (Crisp et al., 1993; Fentiman, 1991) . Therefore, in terms of their lymph node status, many of our FIS-detected cancers behave more like symptomatic than screen-detected cancers.
The two main prerequisites for a reduction in/breast cancer mortality from the breast screening programme are (1) a more favourable stage distribution in screen-detected cancers, with fewer nodal metastases at presentation, and (2) a low incidence of cancers presenting with symptoms between screening rounds (interval cancers). In the North West Region, the incidence of interval cancers in the third year after breast screening approaches that which would be expected in the absence of screening (Woodman et al., 1995) . This suggests that a screening interval of 3 years is too long. The screening interval may have to be shortened to 2 years to reduce the incidence of interval cancers. Although no evidence as yet exists, a shortening of the screening interval may also be required to reduce the incidence of nodal metastases in FIS-detected cancers.
In conclusion, knowledge of axillary lymph node status allows accurate selection of those women requiring systemic adjuvant chemotherapy. Inadequate staging will result in a proprotion of these women receiving suboptimum therapy. It is also imperative to the monitoring of the UK screening programme, that histological evidence of node status be available on all patients at high risk of nodal metastases (Alexander et al., 1994) .
We believe that our recommendations for small and welldifferentiated cancers detected at the PS remain valid. However, in the light of our finding of a higher incidence of node positivity in FIS-detected cancers (with the possible exception of grade I cancers), we now consider surgical staging of the axilla essential for all cancers detected at the FIS, until more reliable predictors of biological aggressiveness and cancer prognosis are identified.
